CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq: CAMP) granted options covering 30,000 common shares to two newly hired employees on November 16, 2026.
The employment inducement grants carry a $3.86 exercise price, equal to the stock’s closing price on the grant date, and a ten-year term. Vesting spans four years: 25% vests on the first anniversary of each employee’s employment start, followed by 36 equal monthly installments, subject to continued service. The grants fall under the 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 30,000 shares at a $3.86 exercise price create potential dilution if exercised.
Key Figures
- Option shares
- 30,000 shares
- Granted to two newly hired employees
- Exercise price
- $3.86 per share
- Equal to the Nov. 16 closing price; matches the prior daily close
- Option term
- 10 years
- Term of each inducement grant
- Vesting period
- 4 years
- Subject to continued employee service
- Initial vesting
- 25%
- Vests on the one-year anniversary of the employee’s first day
- Subsequent vesting installments
- 36 equal monthly installments
- Remaining option shares vest after the initial one-year anniversary
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on November 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase 30,000 shares of the Company’s common stock to two newly hired employees of the Company, each as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
The Inducement Grants each have a ten-year term and an exercise price per share of
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Sofia Bermudez
LifeSci Communications
sbermudez@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.